A Phase 1, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of AG-348 in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Mitapivat (Primary)
- Indications Haemolytic anaemia
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 17 Oct 2017 Status changed from recruiting to completed.
- 16 Aug 2017 New trial record